Brief: Ampio Pharmaceuticals Details Early Positive Results For Inhaled Ampion In Covid-19 Respiratory Distress

Ampio Pharmaceuticals

16/03/2021 13:17

March 16 (Reuters) - Ampio Pharmaceuticals Inc  AMPE.A :
    * AMPIO PHARMACEUTICALS DETAILS EARLY POSITIVE RESULTS FOR
INHALED
AMPION IN COVID-19 RESPIRATORY DISTRESS
    * AMPIO PHARMACEUTICALS INC - AMPION DEMONSTRATED
IMPROVEMENT IN
ALL-CAUSE MORTALITY IN COVID-19 PATIENTS COMPARED TO STANDARD OF
CARE
    * AMPIO PHARMACEUTICALS INC - PATIENTS WHO RECEIVED AMPION
REQUIRED LESS HOSPITALIZATION TIME.
    * AMPIO PHARMACEUTICALS INC - ADVERSE EVENTS WERE SAME
BETWEEN
AMPION AND STANDARD OF CARE
    * AMPIO PHARMACEUTICALS INC - NO DRUG-RELATED SERIOUS
ADVERSE
EVENTS HAVE BEEN REPORTED.
    * AMPIO PHARMACEUTICALS - PROVIDES UPDATES ON FORTHCOMING
PHASE I
CLINICAL TRIAL UTILIZING INHALED AMPION TO TREAT "LONG HAULER"
COVID-19 SYMPTOMS
    * AMPIO PHARMACEUTICALS INC - TRIAL PROTOCOL IS BEING
FINALIZED,
WITH COMMENCEMENT OF STUDY EXPECTED BY MID-Q2 2021

Source text for Eikon:  ID:nPn2VTqwka 
Further company coverage:  AMPE.A 

 ((Reuters.Briefs@thomsonreuters.com;))